Earnings Call · Q3 FY2021·2021-10-28

Q3 21EPS -100.00%*·Rev n/aQ2 21EPS -100.00%*·Rev n/aQ1 21EPS -100.00%*·Rev n/aQ4 20EPS -66.67%·Rev n/a⚠ consensus missing

NovoCure Ltd NVCR

Ingrid Goldberg — Investor Relations

Bill Doyle — Executive Chairman

Asaf Danziger — Chief Executive Officer

Ashley Cordova — Chief Financial Officer

−8.2%1d on move date−9.1% vs SPY3d−2.5%5d−0.4%

Research tier

Behavioral profile computed for 4 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more NVCR calls or request research access.

More NVCR calls Browse calls Request research access